Health Catalyst (NASDAQ:HCAT – Get Free Report) had its price objective dropped by analysts at Evercore ISI from $11.00 to $10.00 in a report released on Friday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Evercore ISI’s price target suggests a potential upside of 31.06% from the stock’s previous close.
HCAT has been the subject of a number of other research reports. Royal Bank of Canada cut their price target on shares of Health Catalyst from $13.00 to $8.00 and set a “sector perform” rating for the company in a research note on Monday, October 30th. Piper Sandler upped their target price on shares of Health Catalyst from $11.00 to $12.00 and gave the stock an “overweight” rating in a research report on Friday, December 22nd. Barclays assumed coverage on Health Catalyst in a research report on Wednesday, January 3rd. They set an “overweight” rating and a $14.00 price target on the stock. JPMorgan Chase & Co. upgraded Health Catalyst from a “neutral” rating to an “overweight” rating and cut their price objective for the stock from $14.00 to $11.00 in a report on Wednesday, December 13th. Finally, Canaccord Genuity Group decreased their price objective on Health Catalyst from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Friday. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $13.15.
Health Catalyst Price Performance
Insider Buying and Selling
In related news, insider Linda Llewelyn sold 3,163 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $10.83, for a total value of $34,255.29. Following the completion of the sale, the insider now owns 68,048 shares of the company’s stock, valued at $736,959.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.70% of the stock is owned by insiders.
Institutional Trading of Health Catalyst
Several institutional investors have recently added to or reduced their stakes in HCAT. The Manufacturers Life Insurance Company raised its stake in Health Catalyst by 3.8% during the 4th quarter. The Manufacturers Life Insurance Company now owns 22,016 shares of the company’s stock valued at $234,000 after buying an additional 796 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Health Catalyst by 2.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 39,757 shares of the company’s stock worth $464,000 after buying an additional 970 shares in the last quarter. Fairfield Bush & CO. purchased a new stake in shares of Health Catalyst during the first quarter worth about $25,000. Panagora Asset Management Inc. raised its position in shares of Health Catalyst by 3.0% during the first quarter. Panagora Asset Management Inc. now owns 36,670 shares of the company’s stock valued at $428,000 after buying an additional 1,079 shares during the last quarter. Finally, US Bancorp DE lifted its stake in Health Catalyst by 14.0% in the 1st quarter. US Bancorp DE now owns 9,260 shares of the company’s stock worth $242,000 after purchasing an additional 1,139 shares in the last quarter. 86.63% of the stock is currently owned by hedge funds and other institutional investors.
Health Catalyst Company Profile
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company offers data operating system data platform for analytics, and application development and interoperability that provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications designed to analyze the problems faced across clinical and quality, population health, and financial and operational use cases.
Read More
- Five stocks we like better than Health Catalyst
- How to Buy Cheap Stocks Step by Step
- How to invest in airline stocks
- Find and Profitably Trade Stocks at 52-Week Lows
- Dropbox’s stock is a falling knife worth catching
- Profitably Trade Stocks at 52-Week Highs
- Warner Bros. Discover: Debt down, profits up, yet questions remain
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.